Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Kyntra Bio ( (KYNB) ) is now available.
On April 2, 2026, Kyntra Bio, Inc. disclosed it had received a notice from Nasdaq stating the company no longer complies with the Nasdaq Global Select Market requirement for $50 million in total assets and total revenue for the most recently completed fiscal year, or two of the last three fiscal years. This shortfall stems from FibroGen International’s revenue being classified as held for sale and treated as discontinued operations in 2024 and 2025, and Kyntra Bio also fails to meet alternative standards based on shareholders’ equity or market value of listed securities.
The notification does not immediately affect trading of Kyntra Bio’s common stock, but the company has until May 18, 2026, to submit a compliance plan to Nasdaq, which could grant up to a 180-day extension through September 29, 2026, if the plan is accepted. Nasdaq’s review will weigh the likelihood of Kyntra Bio regaining compliance, its historical track record, the causes of its current deficiency, its broader financial condition, and public disclosures, while Kyntra Bio may also evaluate transferring its listing to the Nasdaq Capital Market as a strategic response.
The most recent analyst rating on (KYNB) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Kyntra Bio stock, see the KYNB Stock Forecast page.
Spark’s Take on KYNB Stock
According to Spark, TipRanks’ AI Analyst, KYNB is a Neutral.
The score is held back primarily by weak financial performance (collapsed revenue, persistent operating losses, and ongoing negative free cash flow despite improvement). Technicals also remain bearish with negative MACD and price below key longer-term averages. These are partially offset by a more positive earnings-call outlook (cash runway into 2028, large cost reductions, and early clinical progress), while valuation appears mixed due to an extremely low P/E without dividend support.
To see Spark’s full report on KYNB stock, click here.
More about Kyntra Bio
Kyntra Bio, Inc. operates in the biopharmaceutical sector, with its business previously including revenue from FibroGen International, which has been reclassified as held for sale and reported in discontinued operations for 2024 and 2025. The company’s common stock is currently listed on the Nasdaq Global Select Market, but it does not meet certain continued listing standards tied to financial thresholds.
Average Trading Volume: 33,481
Technical Sentiment Signal: Strong Sell
Current Market Cap: $29.54M
For a thorough assessment of KYNB stock, go to TipRanks’ Stock Analysis page.